Market Overview

BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019

Share:

CAMBRIDGE, Mass. and BEIJING, China, Sept. 26, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical data on its investigational anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib will be presented in five poster presentations at the European Society for Medical Oncology (ESMO) Congress 2019, taking place September 27 – October 1, 2019 in Barcelona, Spain.

Poster Presentations:

Title: Population Pharmacokinetics of Tislelizumab in Patients with Advanced Tumors
Presentation #: 483P
Date: Saturday, September 28
Time: 12:00 – 13:00 CEST
Location: Poster Area (Hall 4)
Presenter: Chi-Yuan Wu, Ph.D., BeiGene


Title: Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors
Presentation #: 482P
Date: Saturday, September 28
Time: 12:00 – 13:00 CEST
Location: Poster Area (Hall 4)
Presenter: Chi-Yuan Wu, Ph.D., BeiGene


Title: Updated Results of the PARP1/2 Inhibitor Pamiparib in Combination with Low-dose Temozolomide in Patients with Locally Advanced or Metastatic Solid Tumors
Presentation #: 451PD
Date: Saturday, September 28
Time: 16:30 – 18:00 CEST
Location: Alicante Auditorium (Hall 3)
Presenter: Agostina Stradella, M.D., Catalan Institute of Oncology, Spain


Title: Safety, Antitumor Activity, and Pharmacokinetics of Pamiparib, a PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors: Updated Phase 1 Dose-Escalation/Expansion Results
Presentation #: 452PD
Date: Saturday, September 28
Time: 16:30 – 18:00 CEST
Location: Alicante Auditorium (Hall 3)
Presenter: Mark Voskoboynik, MBBS, FRACP, Nucleus Network, Australia


Title: First Report of Efficacy and Safety from a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma in Asian Patients
Presentation #: 920P
Date: Monday, September 30
Time: 12:00 – 13:00 CEST
Location: Poster Area (Hall 4)
Presenter: Dingwei Ye, M.D., Ph.D., Fudan University Cancer Institute, China
   

About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,700 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.1

   
Investor Contact Media Contact
Craig West Liza Heapes
+1 857-302-5189 +1 857-302-5663
ir@beigene.com media@beigene.com


 

1 ABRAXANE®, REVLIMID® and VIDAZA® are registered trademarks of Celgene Corporation.

Primary Logo

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com